These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

544 related items for PubMed ID: 16052584

  • 1. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
    Heiberg MS, Nordvåg BY, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
    [Abstract] [Full Text] [Related]

  • 2. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.
    Boonen A, Patel V, Traina S, Chiou CF, Maetzel A, Tsuji W.
    J Rheumatol; 2008 Apr; 35(4):662-7. PubMed ID: 18278836
    [Abstract] [Full Text] [Related]

  • 3. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy.
    Davis JC, van der Heijde D, Dougados M, Woolley JM.
    Arthritis Rheum; 2005 Aug 15; 53(4):494-501. PubMed ID: 16082640
    [Abstract] [Full Text] [Related]

  • 4. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS, Koldingsnes W, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2008 Feb 15; 59(2):234-40. PubMed ID: 18240258
    [Abstract] [Full Text] [Related]

  • 5. Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy.
    Wolfe F, Michaud K.
    J Rheumatol; 2007 Aug 15; 34(8):1674-83. PubMed ID: 17611989
    [Abstract] [Full Text] [Related]

  • 6. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response.
    Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE, Perfetto EM.
    Am J Manag Care; 2002 Mar 15; 8(3):231-40. PubMed ID: 11915973
    [Abstract] [Full Text] [Related]

  • 7. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A.
    Isr Med Assoc J; 2008 Apr 15; 10(4):277-81. PubMed ID: 18548981
    [Abstract] [Full Text] [Related]

  • 8. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
    Braun J, McHugh N, Singh A, Wajdula JS, Sato R.
    Rheumatology (Oxford); 2007 Jun 15; 46(6):999-1004. PubMed ID: 17389658
    [Abstract] [Full Text] [Related]

  • 9. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD, Sack KE, Davis JC.
    N Engl J Med; 2002 May 02; 346(18):1349-56. PubMed ID: 11986408
    [Abstract] [Full Text] [Related]

  • 10. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.
    Tse SM, Burgos-Vargas R, Laxer RM.
    Arthritis Rheum; 2005 Jul 02; 52(7):2103-8. PubMed ID: 15986366
    [Abstract] [Full Text] [Related]

  • 11. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L, Pope JE, Payne M.
    J Rheumatol; 2009 Jul 02; 36(7):1421-8. PubMed ID: 19487267
    [Abstract] [Full Text] [Related]

  • 12. Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis.
    Chen JS, Makovey J, Lassere M, Buchbinder R, March LM.
    Arthritis Care Res (Hoboken); 2014 Mar 02; 66(3):464-72. PubMed ID: 24022870
    [Abstract] [Full Text] [Related]

  • 13. [Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis].
    Wallenius M, Rødevand E, Skomsvoll JF.
    Tidsskr Nor Laegeforen; 2005 Jun 16; 125(12):1664-6. PubMed ID: 15976836
    [Abstract] [Full Text] [Related]

  • 14. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
    de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, Hazenberg BP, Wolbink GJ.
    Arthritis Rheum; 2009 Nov 15; 61(11):1484-90. PubMed ID: 19877087
    [Abstract] [Full Text] [Related]

  • 15. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.
    Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, Dorrier C, Thompson A.
    Arthritis Rheum; 2000 Mar 15; 43(3):506-14. PubMed ID: 10728742
    [Abstract] [Full Text] [Related]

  • 16. Sleep disturbance in patients with rheumatoid arthritis: evaluation by medical outcomes study and visual analog sleep scales.
    Wolfe F, Michaud K, Li T.
    J Rheumatol; 2006 Oct 15; 33(10):1942-51. PubMed ID: 16960928
    [Abstract] [Full Text] [Related]

  • 17. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
    Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, Klareskog L, Ulfgren AK.
    Arthritis Rheum; 2005 Jan 15; 52(1):61-72. PubMed ID: 15641091
    [Abstract] [Full Text] [Related]

  • 18. Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis.
    De Filippis L, Caliri A, Anghelone S, Scibilia G, Lo Gullo R, Bagnato G.
    Panminerva Med; 2006 Jun 15; 48(2):129-35. PubMed ID: 16953150
    [Abstract] [Full Text] [Related]

  • 19. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
    Ernestam S, Hafström I, Werner S, Carlström K, Tengstrand B.
    J Rheumatol; 2007 Jul 15; 34(7):1451-8. PubMed ID: 17477470
    [Abstract] [Full Text] [Related]

  • 20. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
    Maksymowych WP, Poole AR, Hiebert L, Webb A, Ionescu M, Lobanok T, King L, Davis JC.
    J Rheumatol; 2005 Oct 15; 32(10):1911-7. PubMed ID: 16206346
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.